drugset
drugset / Trial / NCT03927352

The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis

NCT03927352 ↗

Phase 3 Unknown 330 enrolled Sinocelltech Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this research study is to compare the efficacy and safety of SCT630 and adalimumab (HUMIRA®) in adults with plaque psoriasis.

Timeline

Start
2019-09-05
Primary completion
2021-12-31
Completion
2022-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Adalimumab Monoclonal antibody 40 mg Subcutaneous
Subject SCT630 Unknown 40 mg Subcutaneous

Indications

psoriasis